MétaCan
Menu
← Back to cohort

NeoPancONE: GATA6 expression as a predictor of benefit to peri-operative modified FOLFIRINOX in resectable pancreatic adenocarcinoma (r-PDAC): A multicentre phase II study.

2025· article· en· W4410816903 on OpenAlexaffabout
Ronan Andrew McLaughlin, Derek J. Jonker, Paul J. Karanicolas, Yoo‐Joung Ko, Stephen Welch, Daniel J. Renouf, Kimberly A. Bertens, Carol-Anne Moulton, Michael J. Raphael, Shiva Jayaraman, Xiang Y. Ye, Amy Zhang, Tae Kyoung Kim, Korosh Khalili, Kai Duan, Sandra E. Fischer, Grainne M. O’Kane, Anna Dodd, Steven Gallinger, Jennifer J. Knox

Bibliographic record

VenueJournal of Clinical Oncology · 2025
Typearticle
Languageen
FieldMedicine
TopicPancreatic and Hepatic Oncology Research
Canadian institutionsOntario Institute for Cancer ResearchCancer Care OntarioSt. Michael's HospitalHealth Sciences CentreSunnybrook Health Science CentreOttawa HospitalPrincess Margaret Cancer CentreToronto General HospitalUniversity of TorontoUniversity Health Network
Fundersnot available
KeywordsMedicineFOLFIRINOXAdenocarcinomaOncologyInternal medicinePancreatic ductal adenocarcinomaGemcitabinePancreatic cancerGastroenterologyChemotherapyOxaliplatinCancerColorectal cancer

Abstract

fetched live from OpenAlex

4011 Background: Modified FOLFIRINOX (mFFX) is increasingly used in the perioperative setting in r-PDAC and patients (pts) would benefit from a biomarker approach. GATA6 expression enriches for the classical RNA subtype, associated with improved OS in advanced PDAC. Low expression identifies the basal subtype which may predict mFFX resistance. NeoPancONE is a single arm Phase II multicentre study evaluating clinical outcomes and investigating GATA6 as a biomarker of response to perioperative mFFX in r-PDAC. Methods: Pts were enrolled following central radiology review (CRR) and underwent an EUS FNB for GATA6 in-situ hybridization (ISH). Six cycles of mFFX were planned pre and postoperatively. The primary endpoint was 1 yr event-free survival (EFS) according to GATA6 ISH (high vs low). Secondary endpoints include OS, RECIST response, SAEs, R0 resection rates and RNA subtyping by PurIST. Statistical assumptions used a ratio of 3:1 GATA6 high:low, with a 1 yr EFS of 65% for high and 34% for low (HR 2.5, 80% power, 2 sided alpha 0.05). KM method and log-rank test were used. Results: Between Sep-2020– Sep 2023, 146 pts were screened and 84 enrolled (58%) at 8 Canadian centres. CRR deemed 39 (27%) ineligible. Clinical data are summarized (Table). GATA6 ISH was analysed in 74 (88%); 62 (84%) were high, 16% low. At a median follow up of 24.5 mos, the med EFS and OS in the ITT were 16.1 mos (95 CI; 13-21) and 34.2 mos (95 CI; 28-NE). Med OS in the 73 pts who underwent surgery was 35.6 mos (95 CI 33-NE). The 1 yr EFS was 71% in GATA6 high vs 58% in GATA6 low p= 0.53. 1 yr OS was 87% in high vs 75% for low p= 0.29. The proportion progressing within 6 mos of enrollment in the GATA6 low group was significantly higher (42% vs 12% p=0.02). PuriST subtyping was reported in 49 (67%) resections; 14% basal, 86% classical. The 1 yr EFS was 79% in classical vs 43% in the basal subtype p=0.1. The 1 yr OS was 95% in classical vs 57% in basal p=0.034. Conclusions: This is one of the first trials in r-PDAC to identify potential biomarkers to predict perioperative mFFX response. GATA6 by ISH can be assessed on baseline tissue. GATA6 high is a prognostic biomarker, although NS, trends towards improved EFS and an encouraging OS. Disease progression within 6 months of enrollment occurs in nearly 50% of patients with low GATA6 expression. Neoadjuvant mFFX should not be the standard of care in these patients. Basal/Classical subtyping had stronger prognostic value than GATA6 and should be considered at baseline EUS FNB for future perioperative strategies in r-PDAC studies. Clinical trial information: NCT04472910 . Characteristic n=84 Age med. (range) yrs 64 (44, 83) Baseline EUS FNB tissue n (%) 83 (98) Pre-op completed 6 cycles n (%) 62 (74) Pre-op RECIST CR/PR/SD/PD/NE % 1/18/64/11/6 Surgery Completed Y/N n (%) / R0 / R1 n (%) 73 (87) / 11(13) / 62 (85) / 11 (15) Adjuvant Chemotherapy Y / N n (%) 63 (86) / 10 (14) mFFX associated SAE ≥G3 n (%) 13 (15) Pre-op mFFX related deaths 3 (4)

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.008

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.001
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0010.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.108
GPT teacher head0.517
Teacher spread0.408 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations6
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicPancreatic and Hepatic Oncology Research→French-language works237,207→